MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

Rhea-AI Summary

MIMEDX (NASDAQ: MDXG) has published significant health economics data in the Journal of Drugs in Dermatology regarding their EPIFIX® placental allograft product for wound reconstruction after Mohs surgery. The study of 429 Mohs patients demonstrated superior outcomes compared to traditional methods. Key findings include: - 97.2% of EPIFIX patients experienced no complications vs 78.7% with traditional methods - Average length of care reduced to 33.3 days vs 48.3 days for autologous tissue repairs - Substantial cost savings achieved through fewer complications and reduced additional procedures The data is particularly significant as Mohs surgery is performed over 850,000 times annually in the U.S. for treating common skin cancers. This research supports EPIFIX as an effective alternative to traditional surgical methods, particularly beneficial for high-risk surgeries and hospital systems focused on health economics.

Positive

• 97.2% of patients using EPIFIX experienced no complications vs 78.7% with traditional methods
• Reduced average length of care by 15 days (33.3 vs 48.3 days)
• Cost savings achieved through fewer postoperative complications
• Large market opportunity with over 850,000 annual Mohs procedures in the U.S.

Negative

• None.

Insights

Healthcare Economics Expert

MIMEDX's EPIFIX study shows significant cost-effectiveness in Mohs surgery with reduced complications and faster healing, strengthening value proposition for hospital adoption.

The publication of health economics data for MIMEDX's EPIFIX placental allograft demonstrates compelling value in the 850,000+ annual Mohs Micrographic Surgery (MMS) procedures performed in the US. This retrospective study of 429 patients reveals dual benefits critical to healthcare purchasing decisions: improved outcomes and reduced resource utilization.

The 18.5 percentage point reduction in complications (97.2% vs 78.7% complication-free rate) represents substantial potential savings for healthcare systems by preventing costly adverse events and additional interventions. The economic impact is further strengthened by the 31% faster healing time (33.3 vs 48.3 days), which directly translates to fewer follow-up visits and reduced clinical resource consumption.

This data arrives at an opportune moment as healthcare systems increasingly prioritize evidence-based economic outcomes alongside clinical efficacy. The comprehensive health economics profile positions EPIFIX favorably in value assessment frameworks that hospitals use for purchasing decisions. For hospital administrators under pressure to reduce costs while maintaining quality, these findings provide quantifiable metrics supporting adoption.

While publication of economic data represents just one step in the complex pathway to widespread clinical integration, it addresses a critical barrier to adoption. The reduced treatment duration and complication rates align perfectly with current healthcare incentives focusing on episode-of-care costs rather than individual product pricing alone. This strengthens MIMEDX's value proposition as they expand their product applications beyond their traditional wound care markets.

Dermatology Surgeon

EPIFIX demonstrates superior outcomes in post-Mohs reconstruction with 97.2% complication-free rate versus 78.7% with traditional approaches, potentially changing treatment protocols.

MIMEDX's study on EPIFIX (Dehydrated Human Amnion Chorion Membrane) for post-Mohs reconstruction addresses a significant clinical need in dermatologic surgery. Traditional autologous reconstruction techniques, while effective, create donor site morbidity by requiring tissue harvesting from elsewhere on the patient's body.

The clinical implications are substantial - achieving a 97.2% complication-free rate compared to 78.7% with conventional approaches represents a meaningful improvement for a procedure performed over 850,000 times annually in the US. For context, complications following Mohs surgery can lead to poor cosmetic outcomes, particularly problematic given these procedures often address cancers in highly visible facial areas.

The 15-day reduction in healing time (33.3 versus 48.3 days) significantly improves patient quality of life and functional recovery. This faster resolution translates to reduced patient burden and potentially quicker return to normal activities - critical factors often overlooked in purely clinical assessments.

For Mohs surgeons, this evidence supports an alternative reconstruction pathway for challenging patients including elderly individuals with poor skin quality, patients with comorbidities affecting wound healing, or those with limited donor tissue availability. While the retrospective study design provides real-world evidence, it does have inherent limitations compared to prospective randomized trials.

These findings align with the growing interest in placental-derived products for their regenerative properties and reduced donor site morbidity across reconstructive applications. The data provides clinically relevant evidence to inform treatment selection for the common cancers these procedures typically address.

Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company’s EPIFIX® Placental Allograft Product

MARIETTA, Ga., May 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of its health economics data for reconstruction of cutaneous wounds with EPIFIX^® (Dehydrated Human Amnion Chorion Membrane, or DHACM) following Mohs surgery. The study has been published in the May 2025 issue of Journal of Drugs in Dermatology: “Placental allograft reconstruction of cutaneous wounds following Mohs surgery: a propensity score-matched comparative cost-effectiveness analysis.”

Mohs surgery is widely accepted as the gold standard for treating many types of skin cancer, including basal and squamous cell carcinomas, which are the most common cancers in the United States. MMS is performed over 850,000 times per year in the U.S., primarily by specially trained dermatologists operating in an outpatient setting. The procedure, which involves the removal of layers of cancerous skin tissue, typically ends with an autologous tissue-based closure over the treatment area. However, over the last several years, practitioners have increasingly started to evaluate the utility of placental allografts, such as EPIFIX, to aid in the closure of the impacted surface.

“We are thrilled to continue expanding the number of specialties and treatment applications that see real-world results with our products, both in terms of clinical success and cost-effectiveness,” said Joseph H. Capper, MIMEDX Chief Executive Officer. “This retrospective study of 429 Mohs patients demonstrates the unique ability of our placental allografts to provide an alternative for those who are not suitable candidates for traditional surgical methods. We expect the data collected to inform clinicians and health policy makers of the benefits of innovative approaches in high-risk surgeries, particularly as hospital systems focus on health economics as a driving factor in decision-making.”

In the study, DHACM significantly reduced adverse post-repair sequelae, with 97.2% of patients experiencing no complications compared to 78.7% with traditional methods such as autologous tissue-based flaps and grafts. Placental allografts lead to substantial savings in these procedures by minimizing postoperative complications and reducing the need for additional procedures. Patients treated with placental tissue also reached closure faster, with an average length of care of 33.3 days compared to 48.3 days for those with autologous tissue repairs.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

FAQ

What are the key benefits of MIMEDX EPIFIX for Mohs surgery patients?

EPIFIX demonstrated 97.2% complication-free outcomes (vs 78.7% traditional), reduced care time to 33.3 days (vs 48.3 days), and achieved cost savings through fewer complications and procedures.

How many Mohs surgeries are performed annually in the United States?

Over 850,000 Mohs surgeries are performed annually in the U.S., primarily by specially trained dermatologists in outpatient settings.

What is the success rate of MDXG's EPIFIX in Mohs surgery?

According to the study, 97.2% of patients treated with EPIFIX experienced no complications, compared to 78.7% with traditional methods like autologous tissue-based flaps and grafts.

How does EPIFIX reduce healthcare costs in Mohs surgery?

EPIFIX reduces costs by minimizing postoperative complications, reducing the need for additional procedures, and shortening the length of care by approximately 15 days compared to traditional methods.